Members |
targetComponentId |
Adrenal disorders: [other] or [Conn's syndrome] or [hyperaldosteronism] or [Waterhouse-Friderichen] |
Primary aldosteronism |
Adrenal disorders: [other] or [Conn's syndrome] or [hyperaldosteronism] or [Waterhouse-Friderichen] |
Primary aldosteronism |
Adrenal disorders: [other] or [Conn's syndrome] or [hyperaldosteronism] or [Waterhouse-Friderichen] |
Hyperaldosteronism |
Adrenal disorders: [other] or [Conn's syndrome] or [hyperaldosteronism] or [Waterhouse-Friderichen] |
Hyperaldosteronism |
Adrenal haemorrhage |
Adrenocortical haemorrhage |
Adrenal haemorrhage |
Adrenal hemorrhage |
Adrenal hypertrophy or hyperplasia |
Enlarged adrenal gland (disorder) |
Adrenal hypertrophy or hyperplasia |
Adrenal hyperplasia (disorder) |
Adrenal imaging |
Adrenal radioisotope scan (procedure) |
Adrenal imaging |
Adrenal imaging (procedure) |
Adrenalectomy of remaining gland |
Excision of left adrenal gland (procedure) |
Adrenalectomy of remaining gland |
Excision of right adrenal gland (procedure) |
Adrenaline 1:1000 1mg/1mL injection |
Product containing precisely epinephrine (as epinephrine bitartrate) 1 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Adrenogenital disorders |
Virilisation-adrenogenital syndrome |
Adrenogenital disorders |
Adrenogenital disorder |
Adrenogenital disorders |
Achard-Thiers syndrome |
Adrenogenital disorders |
Feminisation-adrenogenital syndrome |
Adsorbed diphtheria+tetanus vaccine injection suspension 0.5mL prefilled syringe |
Clostridium tetani and Corynebacterium diphtheriae antigens only vaccine product |
Adsorbed tetanus vaccine injection solution ampule |
Vaccine product containing only Clostridium tetani toxoid antigen adsorbed (medicinal product) |
Adsorbed tetanus vaccine injection solution prefilled syringe |
Vaccine product containing only Clostridium tetani toxoid antigen adsorbed (medicinal product) |
Adult ABNORMAL - deleted |
Chronic disease monitoring status |
Adult ABNORMAL - deleted |
Chronic disease monitoring status |
Adult N types |
An evaluation of the performance of an organ, organ system, or body part |
Adult ascariasis |
Ascariasis caused by adult Ascaris |
Adult health examination |
Adult health examination |
Adult health examination |
Well woman health examination |
Adult health examination |
Triennial health examination |
Adult health examination |
Well man health examination |
Adult health examination |
Adult health examination |
Adult health examination |
Well man health examination |
Adult health examination |
Triennial health examination |
Adult health examination |
Well woman health examination |
Adult infection of intestine caused by Clostridium botulinum |
Adult intestinal botulism (disorder) |
Adult infection of intestine caused by Clostridium botulinum |
Infection of intestine caused by Clostridium botulinum in adulthood (disorder) |
Adult junctional epidermolysis bullosa |
Junctional epidermolysis bullosa mitis |
Adult junctional epidermolysis bullosa |
A form of junctional epidermolysis bullosa characterized by onset in childhood or young adulthood of blistering that first occurs around nails, accompanied by nail dystrophy and shedding, and then affects the hands and feet and, to a lesser extent, the elbows, and knees. Lesions heal with atrophic scarring. Other manifestations include disappearance of dermatoglyphs and palmoplantar hyperhidrosis. Extracutaneous involvement is restricted to soft tissue abnormalities of the oral cavity and enamel defects with development of caries. |
Adult lymphedema |
Primary lymphedema tardum (disorder) |
Adult victim of abuse |
Adult victim of abuse (finding) |
Adult-onset obesity |
Hypertrophic obesity |
Adult-onset obesity |
Adult-onset obesity |
Advance directive signed |
Active living will (finding) |
Advanced cardiopulmonary resuscitation |
Advanced cardiac life support (procedure) |
Advanced cardiopulmonary resuscitation |
Advanced resuscitation efforts that extend beyond basic cardiopulmonary resuscitation. |
Advanced directive signed |
Active living will (finding) |
Advanced directive signed |
Active living will (finding) |
Advanced directive signed |
Active living will (finding) |
Advanced directive signed |
Active living will (finding) |
Advancement of eyelid muscle |
Advancement of eyelid muscle (procedure) |
Advancement of eyelid muscle |
Advancement of eye muscle |
Advancement of pedicle graft |
Advancement of pedicle graft |
Advancement of pedicle graft |
Transection of pedicle graft |
Adventitial dissecting aneurysm |
Adventitial dissecting hemorrhage (morphologic abnormality) |
Adverse cutaneous reaction caused by aromatherapy |
Adverse cutaneous reaction to carrier oil (disorder) |
Adverse cutaneous reaction caused by aromatherapy |
Adverse cutaneous reaction to volatile oil (disorder) |
Adverse cutaneous reaction caused by chinese traditional herbal medicine |
Adverse cutaneous reaction to herbal medicine |
Adverse drug event resulting from treatment of disorder |
All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). |
Adverse drug reaction resulting from treatment of disorder |
All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). |
Adverse effect of correct biological substance after proper administration |
Adverse reaction to biological substance |
Adverse effect of physical agent |
Injury by causative force |
Adverse effect of radiation therapy |
Late effect of radiation therapy (disorder) |
Adverse effect of radiation therapy |
Disorder due to radiotherapy (disorder) |
Adverse effect, caused by correct medicinal substance properly administered |
All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). |
Adverse reaction caused by adrenochrome derivative |
Adverse reaction to adrenochrome |
Adverse reaction caused by analgesics, antipyretics and antirheumatics |
Adverse reaction to antirheumatic |
Adverse reaction caused by analgesics, antipyretics and antirheumatics |
Adverse reaction to antipyretic |
Adverse reaction caused by analgesics, antipyretics and antirheumatics |
Analgesic adverse reaction |
Adverse reaction caused by anti-common cold drug |
Cough suppressant adverse reaction |
Adverse reaction caused by anti-common cold drug |
Adverse reaction caused by decongestant (disorder) |
Adverse reaction caused by anti-infective lead compound |
Adverse reaction to lead and/or lead compound (disorder) |
Adverse reaction caused by antidiabetic drug |
Adverse reaction to sulfonyluric hypoglycemic (disorder) |
Adverse reaction caused by antidiabetic drug |
Insulin adverse reaction |
Adverse reaction caused by antidiabetic drug |
Adverse reaction to biguanide hypoglycemic agent (disorder) |
Adverse reaction caused by antiplatelet agent |
Adverse reaction to platelet aggregation inhibitor (disorder) |
Adverse reaction caused by aromatic analgesic |
Analgesic adverse reaction |
Adverse reaction caused by arsenical anti-infective |
Adverse reaction to arsenic and/or arsenic compound |
Adverse reaction caused by bismuth anti-infective compound |
Adverse reaction to bismuth and/or bismuth compound |
Adverse reaction caused by bismuth anti-infective compound |
Anti-infectives adverse reaction |
Adverse reaction caused by bromide |
Adverse reaction caused by bromine and/or bromine compound (disorder) |
Adverse reaction caused by drug acting on bone metabolism |
Adverse reaction to bone resorption inhibitor |
Adverse reaction caused by drug or medicament administered by infusion |
All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). |
Adverse reaction caused by drugs primarily acting on the smooth or skeletal muscles or respiratory system |
All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). |
Adverse reaction caused by eye drug |
All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). |
Adverse reaction caused by glutethimide group |
Adverse reaction to glutethimide |
Adverse reaction caused by hydantoin derivative |
Adverse reaction to hydantoin and/or hydantoin derivative (disorder) |
Adverse reaction caused by hypnotic AND/OR sedative |
Sedative adverse reaction |
Adverse reaction caused by methaqualone compound |
Adverse reaction caused by methaqualone (disorder) |
Adverse reaction caused by mixed bacterial vaccine |
Adverse reaction to bacterial vaccine |
Adverse reaction caused by ovarian hormone |
Progestogen adverse reaction |
Adverse reaction caused by ovarian hormone |
Estrogen adverse reaction |
Adverse reaction caused by over the counter drug |
All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). |
Adverse reaction caused by parasympatholytic and spasmolytic |
Antimuscarinic adverse reaction |
Adverse reaction caused by pipazethate hydrochloride |
Adverse reaction to pipazethate |
Adverse reaction caused by primarily systemic agents |
All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions (from US FDA Guideline for Industry, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). |
Adverse reaction caused by sympatholytic |
Adverse reaction to adrenergic receptor antagonist |
Adverse reaction caused by typhoid and paratyphoid vaccines |
Adverse reaction to typhoid vaccine |
Adverse reaction caused by vaccine properly administered |
Vaccine adverse reaction |
Adverse reaction following injection of neurotoxin |
Adverse reaction following injection of substance |
Adverse reaction to adrenal cortical steroid |
Corticosteroids adverse reaction |
Adverse reaction to alcohol |
Adverse reaction to ethanol |
Adverse reaction to alcohol |
Adverse reaction caused by alcoholic beverage (disorder) |
Adverse reaction to alcohol |
Adverse reaction to substance with alcohol structure |